Co-Diagnostics reveals pricing for $7 million registered direct offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 28 2025
0mins
Securities Purchase Agreement: Co-Diagnostics has entered into a securities purchase agreement with institutional investors to sell 12,727,272 shares of common stock at $0.55 per share.
Financial Details: The offering is expected to generate approximately $7 million in gross proceeds, which will be used for working capital and general corporate purposes.
Closing Date: The offering is anticipated to close on or about October 29, 2025, pending customary closing conditions.
Placement Agent: Maxim Group LLC is serving as the sole placement agent for this offering.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
